Reading path

Reading Cancer Evidence, From Screening to Survival

This path walks you through how oncology evidence is made and judged, moving from the promise and peril of screening to how tumors are staged, how response is measured, and how survival is reported. It is for readers who want to interpret cancer studies and headlines without being misled by early detection or biomarker hype.

The path, step by step

1. 1 Cancer Screening Trades Early Detection Against Overdiagnosis

   5 min read

   Start with the central tension of oncology, that finding cancer earlier can help some people and harm others through overdiagnosis.

2. 2 What Makes a Screening Program Worthwhile, and When Testing Healthy People Does Harm

   6 min read

   Next, learn the general criteria a screening program must meet, which turns the screening debate into a checklist you can apply.

3. 3 Lead-Time Bias: Why Earlier Detection Can Make Survival Look Longer Without Saving Anyone

   6 min read

   Before trusting any survival gain from earlier detection, see why lead-time bias can make screening look effective even when it changes nothing.

4. 4 How Cancer Staging Works and Why Stage Predicts Outcome

   5 min read

   Once a cancer is found, staging is the language that predicts outcome, so it grounds everything that follows.

5. 5 How to Read a Cancer Survival Statistic

   5 min read

   With staging understood, learn how survival statistics are defined and where five-year figures can quietly mislead.

6. 6 Why Overall Survival Is the Gold Standard in Cancer Trials

   5 min read

   Building on survival numbers, see why overall survival remains the benchmark endpoint against which other measures are judged.

7. 7 How Tumor Response Is Measured and Where RECIST Falls Short

   5 min read

   Since many trials report tumor shrinkage rather than survival, learn how response is measured with RECIST and where it breaks down.

8. 8 Predictive Versus Prognostic Cancer Biomarkers Explained

   5 min read

   Modern oncology is biomarker-driven, so distinguish a marker that predicts treatment benefit from one that only forecasts outcome.

9. 9 How Immune Checkpoint Inhibitors Work and Why Response Is Uneven

   4 min read

   Apply that biomarker thinking to a major therapy class whose uneven response makes patient selection the whole game.

10. 10 What ctDNA Minimal Residual Disease Testing Can and Cannot Do

    5 min read

    Close with an emerging blood-based monitoring tool, testing your judgment on evidence that is promising but still maturing.

Each step is a full article on the Reading the Evidence blog.

Back to all reading paths